In Vitro and in Vivo Evaluation of Water-Soluble Iminophosphorane Ruthenium(II) Compounds. A Potential Chemotherapeutic Agent for Triple Negative Breast Cancer

A series of organometallic ruthenium(II) complexes containing iminophosphorane ligands have been synthesized and characterized. Cationic compounds with chloride as counterion are soluble in water (70–100 mg/mL). Most compounds (especially highly water-soluble 2) are more cytotoxic to a number of human cancer cell lines than cisplatin. Initial mechanistic studies indicate that the cell death type for these compounds is mainly through canonical or caspase-dependent apoptosis, nondependent on p53, and that the compounds do not interact with DNA or inhibit protease cathepsin B. In vivo experiments of 2 on MDA-MB-231 xenografts in NOD.CB17-Prkdc SCID/J mice showed an impressive tumor reduction (shrinkage) of 56% after 28 days of treatment (14 doses of 5 mg/kg every other day) with low systemic toxicity. Pharmacokinetic studies showed a quick absorption of 2 in plasma with preferential accumulation in the breast tumor tissues when compared to kidney and liver, which may explain its high efficacy in vivo.

• Publication year

  2014

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2014-11-19

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/jm5012337PMID 25409416PMCID 4266334
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery of a highly tumor-selective organometallic ruthenium(II)-arene complex.

  2014cited by this paper
• Opening the lid on piano-stool complexes: An account of ruthenium(II)–arene complexes with medicinal applications

  2014cited by this paper
• Discovery and investigation of anticancer ruthenium-arene Schiff-base complexes via water-promoted combinatorial three-component assembly.

  2014cited by this paper
• Conformational control of anticancer activity: the application of arene-linked dinuclear ruthenium(II) organometallics

  2014cited by this paper
• Anticancer Ruthenium(η 6 - p -cymene) Complexes of Nonsteroidal Anti-inflammatory Drug Derivatives

  2014cited by this paper
• Recent advances in multinuclear complexes as potential anticancer and DNA binding agents.

  2014cited by this paper
• Toxicity of high glycolic poly(DL-lactic-co-glycolic acid) stabilized ruthenium nanoparticles against human promyelocytic leukemia cells

  2014cited by this paper
• Ruthenium(II)–Arene RAPTA Type Complexes Containing Curcumin and Bisdemethoxycurcumin Display Potent and Selective Anticancer Activity

  2014cited by this paper
• A bis(dipyridophenazine)(2-(2-pyridyl)pyrimidine-4-carboxylic acid)ruthenium(II) complex with anticancer action upon photodeprotection.

  2014cited by this paper
• Anticancer activity of structurally related ruthenium(II) cyclopentadienyl complexes

  2014cited by this paper
• Luminescent iminophosphorane gold, palladium and platinum complexes as potential anticancer agents.

  2014cited by this paper
• Ligand substitutions between ruthenium–cymene compounds can control protein versus DNA targeting and anticancer activity

  2014cited by this paper
• Thermoresponsive organometallic arene ruthenium complexes for tumour targeting

  2014cited by this paper
• Identification of the structural determinants for anticancer activity of a ruthenium arene peptide conjugate.

  2013cited by this paper
• First polymer "ruthenium-cyclopentadienyl" complex as potential anticancer agent.

  2013cited by this paper
• 3-Hydroxyflavones vs. 3-hydroxyquinolinones: structure-activity relationships and stability studies on Ru(II)(arene) anticancer complexes with biologically active ligands.

  2013cited by this paper
• Analysis of the cytotoxic effects of ruthenium–ketoconazole and ruthenium–clotrimazole complexes on cancer cells

  2013cited by this paper
• Potential anticancer heterometallic Fe-Au and Fe-Pd agents: initial mechanistic insights.

  2013cited by this paper
• Ruthenium-based complex nanocarriers for cancer therapy.

  2012cited by this paper
• Interaction of apo-transferrin with anticancer ruthenium complexes NAMI-A and its reduced form.

  2012cited by this paper
• Metals in Medicine

  2012cited by this paper
• Biological activity of ruthenium and osmium arene complexes with modified paullones in human cancer cells

  2012cited by this paper
• New ruthenium(II)-letrozole complexes as anticancer therapeutics.

  2012cited by this paper
• Challenges and Opportunities in the Development of Organometallic Anticancer Drugs

  2012cited by this paper
• Organometallic Palladium Complexes with a Water-Soluble Iminophosphorane Ligand as Potential Anticancer Agents.

  2012cited by this paper
• Cytotoxic hydrophilic iminophosphorane coordination compounds of d⁸ metals. Studies of their interactions with DNA and HSA.

  2012cited by this paper
• Structure-activity relationships of targeted RuII(η6-p-cymene) anticancer complexes with flavonol-derived ligands.

  2012cited by this paper
• Next-generation anticancer metallodrugs.

  2012cited by this paper
• Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.

  2012cited by this paper
• A ruthenocene-PNA bioconjugate--synthesis, characterization, cytotoxicity, and AAS-detected cellular uptake.

  2012cited by this paper
• Designing organometallic compounds for catalysis and therapy.

  2012cited by this paper
• Cycloruthenated Complexes from Iminophosphoranes: Synthesis, Structure, and Reactivity with Internal Alkynes

  2011cited by this paper
• Conjugation of Organoruthenium(II) 3-(1H-Benzimidazol-2-yl)pyrazolo[3,4-b]pyridines and Indolo[3,2-d]benzazepines to Recombinant Human Serum Albumin: a Strategy To Enhance Cytotoxicity in Cancer Cells

  2011cited by this paper
• BH3-only proteins: Orchestrators of apoptosis.

  2011cited by this paper
• Ruthenium(II) arene complexes with oligocationic triarylphosphine ligands: Synthesis, DNA interactions and in vitro properties

  2011cited by this paper
• Iminophosphorane-organogold(III) complexes induce cell death through mitochondrial ROS production.

  2011cited by this paper
• Bioinorganic Medicinal Chemistry: ALESSIO:BIO. INORG. CHEM. O-BK

  2011cited by this paper
• Metal complexes as DNA intercalators.

  2011cited by this paper
• Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.

  2011cited by this paper
• DNA binding to an anticancer organo-ruthenium complex.

  2010cited by this paper
• Synthesis and characterisation of isomeric cycloaurated complexes derived from the iminophosphorane Ph3PNC(O)Ph

  2010cited by this paper
• In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model.

  2010cited by this paper
• Synthesis and biological activities of transition metal complexes based on acetylsalicylic acid as neo-anticancer agents.

  2010cited by this paper
• The crystal structure of BRAF in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase.

  2009cited by this paper
• A ruthenium-containing organometallic compound reduces tumor growth through induction of the endoplasmic reticulum stress gene CHOP.

  2009cited by this paper
• Synthesis of apoptosis-inducing iminophosphorane organogold(III) complexes and study of their interactions with biomolecular targets.

  2009cited by this paper
• Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound.

  2008cited by this paper
• Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds.

  2008cited by this paper
• An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells.

  2007cited by this paper
• 16. (η6‐Hexamethylbenzene)Ruthenium Complexes

  2007cited by this paper
• Inhibitors of cathepsin B.

  2006cited by this paper
• Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology.

  2006cited by this paper
• Ruthenium half-sandwich complexes bound to protein kinase Pim-1.

  2006cited by this paper
• From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).

  2006cited by this paper
• In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes.

  2005cited by this paper
• Ruthenium (II)-Derived Organometallic Compounds Induce Cytostatic and Cytotoxic Effects on Mammalian Cancer Cell Lines through p53-Dependent and p53-Independent Mechanisms

  2005cited by this paper
• Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175

  2005cited by this paper
• Role of an Endoplasmic Reticulum Ca2+-Independent Phospholipase A2 in Cisplatin-Induced Renal Cell Apoptosis

  2004cited by this paper
• Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis.

  2004cited by this paper
• Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy

  2004cited by this paper
• A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent

  2004cited by this paper
• Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms.

  2003cited by this paper
• Synthesis and characterisation of some water soluble ruthenium(II)–arene complexes and an investigation of their antibiotic and antiviral properties

  2003cited by this paper
• Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts.

  2002cited by this paper
• Inhibition of cancer cell growth by ruthenium(II) arene complexes.

  2001cited by this paper
• [Ru(η6-p-cymene)Cl2(pta)] (pta = 1,3,5-triaza-7-phosphatricyclo- [3.3.1.1]decane): a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells

  2001cited by this paper
• Fate of the antimetastatic ruthenium complex ImH [trans-RuCl4(DMSO)Im] after acute i.v. treatment in mice.

  2000cited by this paper
• Unraveling the role of proteases in cancer.

  2000cited by this paper
• A gel mobility shift assay for probing the effect of drug-DNA adducts on DNA-binding proteins.

  1997cited by this paper
• Drug-DNA Interaction Protocols

  1997cited by this paper
• Renal proximal tubular cells in suspension or in primary culture as in vitro models to study nephrotoxicity.

  1990cited by this paper
• Structural aspects of platinum anticancer drug interactions with DNA

  1987cited by this paper
• Synthesis of N-acyl-, N-sulfonyl-, and N-phosphinylphospha-λ5-azenes by a redox-condensation reaction using amides, triphenylphosphine, and diethyl azodicarboxylate

  1985cited by this paper
• Antineoplastic activity and toxicity of an organometallic complex of ruthenium(II) in comparison with cis-PDD in mice bearing solid malignant neoplasms.

  1984cited by this paper
• Principles of fluorescence spectroscopy

  1983cited by this paper
• Tumor uptake of radioruthenium compounds

  1980cited by this paper

• Controlling Stemness in 2D and 3D Models of Triple‐Negative Breast Cancer Using a Ruthenium(II) Arene Complex

  2026cites this paper
• Synthesis, crystal structure, spectroscopic characterization, theoretical studies and cytotoxicity assays of novel two acylhydrazones and its Cu(II) complexes

  2026cites this paper
• Cytotoxic evaluation of dinuclear ruthenium p-cymene complex with the mononuclear counterpart: A structural perspective.

  2026cites this paper
• NMR spectroscopy stability studies of Ru-IM, a prodrug candidate for triple negative breast cancer.

  2026cites this paper
• State of the art in organometallic ruthenium metallodrugs for breast cancer treatment: Advances and innovations

  2025cites this paper
• Unlocking the potential of azide-phosphine Staudinger reaction for the synthesis of poly(arylene iminophosphorane)s and materials therefrom

  2025cites this paper
• Exploring the toxicity of mononuclear piano-stool Ru(II) anticancer agents: A comprehensive literature review

  2025cites this paper
• Enhanced Cytotoxicity of Half-Sandwich Ruthenium(II) Complex Containing Nitro-Substituted Salicyllimidazo[1,5-a]pyridine toward Hormone-Independent Triple-Negative Breast Cancer Cells.

  2025cites this paper
• Gold Acyclic Diaminocarbene Complexes as Selective and Potent Agents for Multitarget Cancer Therapy

  2025cites this paper
• Microwave-assisted synthesis and evaluation of chalcone-ligated molybdenum carbonyl complexes as cytotoxic agents and DNA binders

  2024cites this paper
• Ruthenium-based complexes as anti-tumor agents

  2024cites this paper
• Recent trends in the design and delivery strategies of ruthenium complexes for breast cancer therapy.

  2024cites this paper
• Photoinduced Group Transposition via Iridium-Nitrenoid Leading to Amidative Inner-Sphere Aryl Migration.

  2024cites this paper
• 2-Aryl-1H-imidazo[4,5-f][1,10]phenanthroline-Based Binuclear Ru(II)/Ir(III)/Re(I) Complexes as Mitochondria Targeting Cancer Stem Cell Therapeutic Agents.

  2024cites this paper
• Metal-(Acyclic Diaminocarbene) Complexes Demonstrate Nanomolar Antiproliferative Activity against Triple-Negative Breast Cancer.

  2024cites this paper
• Efficient and Sustainable Electrosynthesis of N-Sulfonyl Iminophosphoranes by the Dehydrogenative P–N Coupling Reaction

  2024cites this paper
• Insights into Mechanisms and Promising Triple Negative Breast Cancer Therapeutic Potential for a Water-Soluble Ruthenium Compound.

  2024cites this paper
• Evaluation of heteroscorpionate ligands as scaffolds for the generation of Ruthenium(II) metallodrugs in breast cancer therapy.

  2024cites this paper
• Triarylphosphine-Coordinated Bipyridyl Ru(II) Complexes Induce Mitochondrial Dysfunction.

  2023cites this paper
• Organometallic d6, d8 and d10 metal complexes for biosensing and imaging, cancer therapy and theranosis

  2023cites this paper
• Ruthenium arene complexes with chalcone ligands incorporating pyridyl and anthryl units: Synthesis, aqueous stability and interaction with quadruplex DNA

  2023cites this paper
• In Vitro and In Vivo Effects of Docetaxel and Dasatinib in Triple-Negative Breast Cancer: A Research Study

  2023cites this paper
• Fine-tuning the cytotoxicity of ruthenium(ii) arene compounds to enhance selectivity against breast cancers

  2023cites this paper
• Ruthenium complexes for breast cancer therapy

  2023cites this paper
• Synthesis, characterization, photophysical and electrochemical properties, and biomolecular interaction of 2,2'-biquinoline based phototoxic Ru(II)/Ir(II) complexes.

  2023cites this paper
• Luminescent 11-{Naphthalen-1-yl}dipyrido[3,2-a:2',3'-c]phenazine-Based Ru(II)/Ir(III)/Re(I) Complexes for HCT-116 Colorectal Cancer Stem Cell Therapy.

  2023cites this paper
• Photoredox Catalytic Phosphine-Mediated Deoxygenation of Hydroxylamines Enables the Construction of N-Acyliminophosphoranes.

  2022cites this paper
• Iminophosphoranes: Synthesis, evolution of synthesis by 31P-NMR, DFT calculations and antioxidant activity

  2022cites this paper
• Construction of N-Acyliminophosphoranes via Iron(II)-Catalyzed Imidization of Phosphines with N-Acyloxyamides.

  2022cites this paper
• Iminophosphoranes (R3P NR′): From terminal to multidentate ligands in organometallic chemistry

  2022cites this paper
• BODIPY as a Multifunctional Theranostic Reagent in Biomedicine: Self‐Assembly, Properties, and Applications

  2022cites this paper
• Ru(II)/amino acid complexes inhibit the progression of breast cancer cells through multiple mechanism-induced apoptosis.

  2021cites this paper
• Synthesis, Characterization, Antimicrobial and Anticancer Activity of New Bidentate Schiff Base Ligand and their Transition Metal(II) Complexes

  2021cites this paper
• Synthesis, structure and cytotoxicity of N,N and N,O coordinated RuII complexes of 3-aminobenzoate Schiff bases against triple-negative breast cancer.

  2021cites this paper
• Evaluation of the In Vitro and In Vivo Efficacy of Ruthenium Polypyridyl Compounds against Breast Cancer

  2021cites this paper
• Ru(II), Ir(III), Re(I) and Rh(III) based complexes as next generation anticancer metallopharmaceuticals.

  2021cites this paper
• Investigation of the Effects and Mechanisms of Anticancer Action of a Ru(II)‐Arene Iminophosphorane Compound in Triple Negative Breast Cancer Cells

  2021cites this paper
• Design concepts of half-sandwich organoruthenium anticancer agents based on bidentate bioactive ligands

  2021cites this paper
• Half-sandwich ruthenium (II) p-cymene complexes based on organophosphorus ligands: Structure determination, computational investigation, in vitro antiproliferative effect in breast cancer cells and antimicrobial activity

  2021cites this paper
• Tridentate 3-Substituted Naphthoquinone Ruthenium Arene Complexes: Synthesis, Characterization, Aqueous Behavior, and Theoretical and Biological Studies

  2021cites this paper
• Cytotoxicity, anti-tumor effects and structure-activity relationships of nickel and palladium S,C,S pincer complexes against double and triple-positive and triple-negative breast cancer (TNBC) cells.

  2021cites this paper
• Detection of Ru potential metallodrug in human urine by MALDI-TOF mass spectrometry: Validation and options to enhance the sensitivity.

  2021cites this paper
• Interfering with Metabolic Profile of Triple-Negative Breast Cancer using Rationally-Designed Metformin Prodrugs.

  2021cites this paper
• Exploring the Potential of Metallodrugs as Chemotherapeutics for Triple Negative Breast Cancer.

  2021cites this paper
• Intracellular Localization Studies of the Luminescent Analogue of an Anticancer Ruthenium Iminophosphorane with High Efficacy in a Triple-Negative Breast Cancer Mouse Model.

  2021cites this paper
• Complexes of Group 7 Metals with Metal-Carbon Sigma and Multiple Bonds

  2021cites this paper
• Carbonyl and Isocyanide Complexes of Manganese

  2021cites this paper
• Safety and Efficacy Evaluation In Vivo of a Cationic Nucleolipid Nanosystem for the Nanodelivery of a Ruthenium(III) Complex with Superior Anticancer Bioactivity

  2021cites this paper
• In vivo anticancer activity of a rhodium metalloinsertor in the HCT116 xenograft tumor model

  2020cites this paper
• Rationally Designed Ruthenium Complexes for Breast Cancer Therapy

  2020cites this paper
• Anticancer activity studies of novel metal complexes of ligands derived from polycyclic aromatic compound via greener route

  2020cites this paper
• Multi-target heteroleptic palladium bisphosphonate complexes

  2020cites this paper
• Recent Research Progress on the Quantum Chemistry Study of Metal Complexes with Anticancer Activity

  2020cites this paper
• Novel hybrid materials based on heteroleptic Ru(III) complexes immobilized on SBA-15 mesoporous silica as highly potent antimicrobial and cytotoxic agents

  2020cites this paper
• Recent progress in small molecule agents for the targeted therapy of triple-negative breast cancer.

  2020cites this paper
• Synthesis, characterization and cytotoxic activity of cationic half-sandwich Ru(ii) complexes stabilized by iminophosphorane N,N,S and N,N,Se tridentate ligands

  2020cites this paper
• Multinuclear biologically active Ru, Rh, Os and Ir arene complexes

  2020cites this paper
• Screening and Preliminary Biochemical and Biological Studies of [RuCl(p-cymene)(N,N-bis(diphenylphosphino)-isopropylamine)][BF4] in Breast Cancer Models

  2019cites this paper
• Nuclear localization of dirhodium(ii) complexes in breast cancer cells by X-ray fluorescence microscopy.

  2019cites this paper
• Synthesis, crystal structure and cytotoxicity assays of a copper(II) nitrate complex with a tridentate ONO acylhydrazone ligand. Spectroscopic and theoretical studies of the complex and its ligand

  2019cites this paper
• In vitro and in vivo evaluation of first-generation carbosilane arene Ru(II)-metallodendrimers in advanced prostate cancer

  2019cites this paper
• Biological evaluation of water soluble arene Ru(II) enantiomers with amino-oxime ligands.

  2018cites this paper
• Metal Drugs and the Anticancer Immune Response.

  2018cites this paper
• The trans-[Ru(PPh3)2(N,N-dimethyl-N'-thiophenylthioureato-k2O,S)(bipy)]PF6 complex has pro-apoptotic effects on triple negative breast cancer cells and presents low toxicity in vivo.

  2018cites this paper
• Anti-Proliferative and Anti-Migration Activity of Arene–Ruthenium(II) Complexes with Azole Therapeutic Agents

  2018cites this paper
• Non-Platinum Metal Complexes as Potential Anti-Triple Negative Breast Cancer Agents

  2018influential citation
• Pyridazine-based heteroleptic copper(II) complexes as potent anticancer drugs by inducing apoptosis and S-phase arrest in breast cancer cell

  2018cites this paper
• Synthesis, cytotoxicity and anti-metastatic properties of new pyridyl–thiazole arene ruthenium(II) complexes

  2018cites this paper
• Synthesis and preliminary biological evaluation for the anticancer activity of organochalcogen (S/se) tethered chrysin-based organometallic RuII(η6-p-cymene) complexes

  2018cites this paper
• Aminophosphine ligands as a privileged platform for development of antitumoral ruthenium(ii) arene complexes.

  2017cites this paper
• Copper(i) complexes with phosphine derived from sparfloxacin. Part III: multifaceted cell death and preliminary study of liposomal formulation of selected copper(i) complexes.

  2017cites this paper
• The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials.

  2017cites this paper
• Ruthenium Anticancer Agents—From Cisplatin Analogues to Rational Drug Design

  2017cites this paper
• Organoruthenium(II)-Arene Complexes: Structural Building Blocks for Anticancer Drug Discovery

  2017cites this paper
• Ligand Photosubstitution Reactions with Ruthenium Compounds

  2017cites this paper
• Synthesis and analysis of the anticancer activity of Ru(II) complexes incorporating 2-hydroxymethylidene-indene-1,3-dione ligands

  2017cites this paper
• Pyrazine based Pt(II) bis‐alkynyl organometallic complexes: Synthesis, characterization, and cytotoxic effect on A549 human lung carcinoma cells

  2017cites this paper
• Novel piplartine-containing ruthenium complexes: synthesis, cell growth inhibition, apoptosis induction and ROS production on HCT116 cells

  2017cites this paper
• A Review of Ruthenium Complexes Activities on Breast Cancer Cells.

  2017cites this paper
• Ruthenium complexes with phenylterpyridine derivatives target cell membrane and trigger death receptors-mediated apoptosis in cancer cells.

  2017cites this paper
• p53 dependent apoptosis and cell cycle delay induced by heteroleptic complexes in human cervical cancer cells.

  2017cites this paper
• Recent development of transition metal complexes with in vivo antitumor activity.

  2017cites this paper
• Lipid-based carriers for controlled delivery of nitric oxide

  2017cites this paper
• Selective Ru(II)/lawsone complexes inhibiting tumor cell growth by apoptosis.

  2017cites this paper
• Unusual mode of protein binding by a cytotoxic π-arene ruthenium(ii) piano-stool compound containing an O,S-chelating ligand.

  2016cites this paper
• Development of Arene Ruthenium Antitumor Complexes.

  2016cites this paper
• Ruthenium(II) Complexes as Potential Apoptosis Inducers in Chemotherapy.

  2016cites this paper
• Structural Determinants of p53-Independence in Anticancer Ruthenium-Arene Schiff-Base Complexes.

  2016cites this paper
• Bioactive gold(i) complexes with 4-mercaptoproline derivatives.

  2016cites this paper
• Photoswitchable arene ruthenium and pentamethylcyclopentadienyl rhodium complexes containing o-sulfonamide azobenzene ligands: Synthesis, characterization and cytotoxicity

  2016cites this paper
• Ruthenium(II) arene complexes containing benzhydrazone ligands: synthesis, structure and antiproliferative activity

  2016cites this paper
• Interactions between proteins and Ru compounds of medicinal interest: A structural perspective

  2016cites this paper
• Synthesis, structure and chemistry of dinuclear and trinuclear hexamethylbenzene ruthenium acyl thiolate compounds

  2016cites this paper
• Non-symmetric CNS-Pt(II) pincer complexes including thioether functionalized iminophosphoranes. Evaluation of their in vitro anticancer activity

  2016cites this paper
• Insights into the in vitro Anticancer Effects of Diruthenium‐1

  2016cites this paper
• Upconverting Nanoparticles Prompt Remote Near-Infrared Photoactivation of Ru(II)-Arene Complexes.

  2016cites this paper
• Synthesis and anticancer activity of carbosilane metallodendrimers based on arene ruthenium(ii) complexes.

  2016cites this paper
• Design, synthesis and characterisation of new chimeric ruthenium(II)-gold(I) complexes as improved cytotoxic agents.

  2015cites this paper
• Cyclometalated Iminophosphorane Gold(III) and Platinum(II) Complexes. A Highly Permeable Cationic Platinum(II) Compound with Promising Anticancer Properties

  2015cites this paper
• Highly cytotoxic bioconjugated gold(I) complexes with cysteine-containing dipeptides.

  2015cites this paper